Global Industry Analysts, Inc., Jan 2011, Pages: 442
Patent Pooling: Yet Another Obstacle
Commercialization: A Road Uphill
Time Line in Gene Therapy Drug Development
Target Diseases and Players Involved
Key Players by Application Area
Table 4: Gene
Datamonitor, March 2009, Pages: 122
40% of total sales; the majority of revenues (60%) was achieved in the rest of world which includes the majority of the high burden countries.
The most significant commercial opportunity exists
Frost & Sullivan, Dec 2004
immense potential for effectively targeting HIV, herpes, malaria, and influenza, meningitis and various types of cancer. Moreover, DNA vaccines have the ability to stimulate potent immune responses without
GlobalData, June 2011, Pages: 39
and commercialization of innovative therapeutic products for the treatment of unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company’s is principally into the developing
Life Science Intelligence, Inc., Jan 2011
This report includes details on over 300 emerging medical technology companies that: have presented at a 2010 Elsevier/Medtech Insight In3 investor/partnering conference; have presented at a 2010
Frost & Sullivan, Oct 2001
and pharmaceutical firm, and critical developments are virtually impossible to track.
Technical Insights report separates the good news from the mundane by providing the following:
- A detailed overview
